22 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
-to-moderate dementia with Lewy bodies (DLB); topline results expected in 2H2024
Initiated site activation and recruitment in Phase 2 START Study in early
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
(COG0203) study of CT1812 in patients with early-stage AD. We received clearance from the FDA to proceed with the START clinical trial and recruitment has
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
-stage AD. We received clearance from the FDA to proceed with the START clinical trial and recruitment has commenced. We intend to enroll 540 adults
8-K
EX-99.1
9twyzam
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
lait77h6
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
0ltfdiaft qw
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
DEF 14A
jkc3yzysf 5es
25 Apr 22
Definitive proxy
5:28pm
S-1
EX-10.24
iqkomz 5lmo9a8qp72m
19 Jul 21
IPO registration
7:02am
S-1
EX-10.25
opbpi
19 Jul 21
IPO registration
7:02am
S-1
EX-10.32
b3afwe2ievbnh9h0o8qg
19 Jul 21
IPO registration
7:02am
S-1
EX-10.33
ctbk417tfbe
19 Jul 21
IPO registration
7:02am
S-1
EX-10.31
b9r3x38qhn x5ivy12v
19 Jul 21
IPO registration
7:02am
S-1
EX-10.27
tf72b9uw
19 Jul 21
IPO registration
7:02am
DRS/A
EX-10.22
269pu0iq35ri
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.21
geq02c98x0oewfych
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.28
brk m78t3yqeu
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.24
yg97eodrd1bhp
23 Jun 21
Draft registration statement (amended)
12:00am